Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Total Liabilities (2017 - 2025)

NovaBridge Biosciences (NBP) has 9 years of Total Liabilities data on record, last reported at $29.6 million in Q4 2025.

  • On a quarterly basis, Total Liabilities rose 156.78% to $29.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.6 million, a 156.78% increase, with the full-year FY2025 number at $29.6 million, up 156.78% from a year prior.
  • Total Liabilities reached $29.6 million in Q4 2025 per NBP's latest filing, up from $18.5 million in the prior quarter.
  • Over the last five years, Total Liabilities for NBP hit a ceiling of $163.6 million in Q4 2022 and a floor of $10.0 million in Q2 2025.
  • A 5-year average of $74.0 million and a median of $29.6 million in 2025 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 90.73% in 2024, then skyrocketed 156.78% in 2025.
  • Tracing NBP's Total Liabilities over 5 years: stood at $162.9 million in 2021, then rose by 0.43% to $163.6 million in 2022, then dropped by 24.05% to $124.3 million in 2023, then crashed by 90.73% to $11.5 million in 2024, then skyrocketed by 156.78% to $29.6 million in 2025.
  • Business Quant data shows Total Liabilities for NBP at $29.6 million in Q4 2025, $18.5 million in Q3 2025, and $10.0 million in Q2 2025.